Macropen 35 mg/ml zrnca za peroralno suspenzijo Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

macropen 35 mg/ml zrnca za peroralno suspenzijo

krka, d.d., novo mesto - miokamicin - zrnca za peroralno suspenzijo - miokamicin 35 mg / 1 ml - miokamicin

Macropen 400 mg filmsko obložene tablete Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

macropen 400 mg filmsko obložene tablete

krka, d.d., novo mesto - midekamicin - filmsko obložena tableta - midekamicin 400 mg / 1 tableta - midekamicin

Microlax 4,465 g/0,45 g/0,0645 g rektalna raztopina Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

microlax 4,465 g/0,45 g/0,0645 g rektalna raztopina

natrijev citrat; sorbitol, tekoči (kristalizirajoči); natrijev lavrilsulfoacetat (70%) - rektalna raztopina - natrijev citrat 0,45 g / 1 vsebnik  sorbitol, tekoči (kristalizirajoči)4,465 g / 1 vsebnik  natrijev lavrilsulfoacetat (70%)0,0645 g / 1 vsebnik; sorbitol, tekoči (kristalizirajoči) 4,465 g / 1 vsebnik  natrijev lavrilsulfoacetat (70%)0,0645 g / 1 vsebnik; natrijev lavrilsulfoacetat (70%) 0,0645 g / 1 vsebnik - natrijev lavrilsulfoacetat in njegove kombinacije

Microlax 4,465 g/0,45 g/0,0645 g rektalna raztopina Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

microlax 4,465 g/0,45 g/0,0645 g rektalna raztopina

natrijev citrat; sorbitol, tekoči (kristalizirajoči); natrijev lavrilsulfoacetat (70%) - rektalna raztopina - natrijev citrat 0,45 g / 1 vsebnik  sorbitol, tekoči (kristalizirajoči)4,465 g / 1 vsebnik  natrijev lavrilsulfoacetat (70%)0,0645 g / 1 vsebnik; sorbitol, tekoči (kristalizirajoči) 4,465 g / 1 vsebnik  natrijev lavrilsulfoacetat (70%)0,0645 g / 1 vsebnik; natrijev lavrilsulfoacetat (70%) 0,0645 g / 1 vsebnik - natrijev lavrilsulfoacetat in njegove kombinacije

Yesafili Evropska unija - slovenščina - EMA (European Medicines Agency)

yesafili

viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - oftalmologi - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.

Byooviz Evropska unija - slovenščina - EMA (European Medicines Agency)

byooviz

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - oftalmologi - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Vabysmo Evropska unija - slovenščina - EMA (European Medicines Agency)

vabysmo

roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - oftalmologi - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).

Ximluci Evropska unija - slovenščina - EMA (European Medicines Agency)

ximluci

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologi - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Ranivisio Evropska unija - slovenščina - EMA (European Medicines Agency)

ranivisio

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologi - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

Angiox Evropska unija - slovenščina - EMA (European Medicines Agency)

angiox

the medicines company uk ltd - bivalirudin - akutni koronarni sindrom - antitrombotična sredstva - angiox je indiciran kot antikoagulant pri odraslih bolnikih s perkutano koronarnim posegom (pci), vključno z bolniki z miokardnim infarktom elevacije st (stemi), ki se podvrže primarni pci. angiox je prikazano tudi za zdravljenje odraslih bolnikov z nestabilno angino pektoris / non-st-segmenta,-dvig miokardni infarkt (ua / nstemi) načrtovana za nujne ali zgodnje intervencije. angiox je treba dajati z aspirinom in clopidogrel.